Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for marrow fat changes after minimal trauma fracture in older women with osteoporosis
ACTRN12611000082909Phase 4Withdrawn
- Sponsor
- Sydney West Area Health Service
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in osteoporosis comparing Zoledronic acid with Placebo saline (2 arms). Primary endpoint: Change in marrow fat in femur and vertebrae. Planned start Feb 2013; status: withdrawn.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ACTRN12611000082909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000082909.